Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property

Canopy Growth Completes Acquisition of MTL Cannabis Creating Canada's Leading Medical Cannabis Business By Revenue

MTLC · Price

Executive Summary

  • Canopy Growth Corporation completed its acquisition of 100% of MTL Cannabis Corp., issuing ~41.2 million Canopy Growth shares and paying approximately C$18.5 million cash to MTL shareholders.
  • The transaction creates Canada’s leading medical cannabis platform, adds high‑quality flower capacity, expands Québec presence, and is expected to generate roughly C$10 million of run‑rate synergies within 18 months, supporting a path to positive adjusted EBITDA by fiscal 2027.
  • Key MTL executives join Canopy Growth’s leadership team; the deal also includes issuance of ~2.96 million shares to former MC shareholders with an 18‑month transfer restriction.

Key Details

  • Consideration: Each MTL share exchanged for 0.32 Canopy Growth common share + C$0.144 cash.
  • Shares Issued: Approximately 41.2 million Canopy Growth shares issued to MTL shareholders.
  • Cash Paid: Approximate cash outlay of C$18.5 million (paid to Odyssey Trust Company in trust for MTL shareholders).
  • Additional Share Issuance: 2,956,391 Canopy Growth shares issued to former MC shareholders; subject to an 18‑month transfer restriction.
  • Synergies: Expected run‑rate synergies of ~C$10 million within 18 months post‑integration.
  • Leadership Integration:
  • Luc Mongeau – CEO (Canopy)
  • Tom Stewart – CFO (Canopy)
  • Christelle Gedeon – Chief Business Development & Corporate Affairs Officer
  • Michael Perron – COO (formerly MTL CEO)
  • Chrissy McHardy – SVP, Human Resources
  • Andrew Bevan – SVP, Medical Sales
  • Jürgen Bickel – Managing Director, Storz & Bickel GMBH
  • Strategic Advisors: Richard Clément and Michel Clément (MTL co‑founders) will serve as strategic advisors.
  • Delisting Timeline: MTL shares expected to be delisted from the Canadian Securities Exchange around 2026‑03‑16.
  • Advisors & Counsel:
  • Canaccord Genuity – exclusive financial advisor to Canopy Growth.
  • Cassels Brock & Blackwell LLP / Paul Hastings LLP – legal counsel to Canopy Growth.
  • Haywood Securities – exclusive financial advisor to MTL’s special committee (fairness opinion).
  • Farris LLP – legal counsel to MTL Cannabis.
  • Strategic Benefits Highlighted:
  • Strengthened Canadian medical cannabis market leadership and revenue share.
  • Expanded high‑quality flower supply for domestic and international (including European) markets.
  • Enhanced presence in Québec, Canada’s second‑largest cannabis market.
  • Accretive, cash‑generating business supporting earnings growth and margin improvement.
  • Forward‑Looking Statements: The release contains numerous forward‑looking statements regarding anticipated benefits, synergies, integration timelines, and financial impacts; risks and uncertainties are detailed in the company’s public filings.

Notable Quotes

“The acquisition of MTL is a defining step forward in strengthening Canopy Growth’s core Canadian business and advancing our path toward sustainable profitability,” – Luc Mongeau, CEO, Canopy Growth.

“We’re proud to join Canopy Growth and begin this next phase as one team,” – Richard Clément, Co‑Founder & former Chief Cultivation Officer, MTL Cannabis.

Read the original news release →

More from MTL Cannabis Corp.